Jun 2
H.C. Wainwright was proud to host over 70 biotech companies at this year's BioConnect Investor Conference at NASDAQ World Headquarters in New York City.
The event brought together some of the most compelling voices across the biotech sector for a day of meaningful dialogue and insight. Our biotech team has published their key takeaways from the discussions, highlighting the central ideas and trends that stood out most.
Read the full report here: lnkd.in/ecjYf57J
4
159
We appreciate Dr. Joe Pantginis of @HCWCO for hosting a fireside chat with $LCTX ‘s @CEO_Culley as part of @HCWCO 4th Annual BioConnect Investor Conference at @NasdaqExchange.
Replay available here: bit.ly/3m7EWIp
#CellTherapy #InvestorRelations #ReplaceandRestore
4
11
612
Good discussion by $IPSC on 813, their T1D program, at HC Wainwright Bioconnect Investor Conference 2026. They are still on track to submit IND this year and will share initial data in H2 2027. Key quote from Brent - "...it is going to take fair amount to time and investment to scale up these therapies to the scale you need to access this type of patient population......the company that does that best is likely to be the company that will own the majority of the market."
I assume that's the reason $LCTX is focused on solving the iPSC derived islet cell challenges - enable viable & profitable commercial scale production of iPSC derived islet cells to address T1D demand.
investors.centurytx.com/even…
2
1
5
1,475
May 22
Voici la transcription de Hansa Biopharma qui a participé à la 4e conférence annuelle des investisseurs BioConnect de HC Wainwright au Nasdaq.$HNSA🚀🚀🚀
1
3
316
ProBioGen management / board background — condensed
ProBioGen AG is a Berlin-based CDMO and technology provider, originally a Charité spin-out, focused on cell-line engineering, process development, GMP manufacturing, viral vaccines, viral vectors, antibodies, proteins, and gene/cell-therapy manufacturing support.
Executive team
Dr. Alfred Merz — CEO
Merz joined ProBioGen in 2024 as COO and interim CEO, then became full CEO as of April 2025. His profile is classic industrial pharma operations: more than 30 years in manufacturing, operational excellence and strategy, including Bayer and Novartis in Europe and the U.S.
Dr. Simon Johannes Bulling — COO, newly joined
Bulling is the key recent appointment.
ProBioGen announced him on 21 April 2026, effective 15 April 2026, as COO. His mandate is to lead the operational business and oversee manufacturing across ProBioGen’s portfolio: proteins, viral vectors, cell and gene therapy. His background includes Celonic, Recipharm, Rentschler Biopharma, Vetter Pharma and Sandoz, with experience in sterile fill-finish, drug substance, drug product, GMP scale-up and multi-site operations.
Dr. Volker Sandig — CSO
Long-term scientific backbone: with ProBioGen since 2000, initiated the company’s cell-line development program, co-inventor of key technologies including AGE1 designer cell lines, GlymaxX and DirectedLuck, and works on viral-vector manufacturing and RNA-delivery platforms. Before ProBioGen, he worked at Merck Research Laboratories in the U.S. on adenoviral/vectored vaccine manufacturing systems.
Andrea Hauptmann — CFO
With ProBioGen since 2009, CFO since 2021, responsible for financial reporting, controlling, funding, cash management and financial risk management.
Dr. Gabriele Schneider — CBO
With ProBioGen since 2002; CBO since 2017; leads business development, commercial, marketing and communications strategy.
Supervisory board — notable profiles
Dr. Wafik Bardissi — Chairman
Chairman and CEO of Minapharm Pharmaceuticals, ProBioGen’s parent-company environment. He founded what ProBioGen describes as the first state-of-the-art biotech manufacturing operation in Africa/MENA in 2001 and signed the deal to acquire ProBioGen in 2010.
His profile also includes medicine/surgery, business IT, operational research, decision sciences and AI.
Importantly, ProBioGen states that in 2010 he was honored with the Knighthood / cavalry of the Pontifical Equestrian Order of St. Gregory the Great by Pope Benedict XVI for pioneering social work. ‼️
Dr. Shaheer Bardissi
Co-CEO and executive board member at Minapharm. His focus is immuno-oncology, vaccines, cell- and gene-based therapies, and expansion of Minapharm’s biologics portfolio across Africa. He previously worked at BioNTech and holds a PhD from Johannes Gutenberg University Mainz focused on gene-based immunotherapy.
Amr Shabrawishi — Co-Chairman
Vice-chairman of Minapharm; also chairman/CEO of Shabrawishi Hospital in Cairo, chairman of Egyptian Biological Science Co. for blood/plasma collection and processing, and board member of Viral Inactivated Plasma Systems, a Swiss plasma viral inactivation/fractionation company.
Prof. Dr.-Ing. Wiltrud Treffenfeldt
Industrial biotech/chemicals profile: Dow, Dow AgroSciences, Degussa/Evonik; CTO for Europe/Middle East/Africa/India from 2011–2019; German bioeconomy councils; Fraunhofer senate; BRAIN Biotech supervisory board.
Klaus Nestler
Life-science finance/M&A profile: Stifel Europe Advisory, ACXIT Capital, BioConnect AG, SBC Warburg, cross-border healthcare capital markets, venture capital and M&A.
Prof. Dr. med. Hans-Dieter Volk
Direct Charité link: former head of the Institute of Medical Immunology at Charité, founding director/speaker of the BIH Center for Regenerative Therapies, senior professor at Charité, focused on translational immunology, immune biomarkers, virus infections in immunocompromised patients, regenerative medicine, and cell/gene therapies.
ProBioGen’s own profile notes that BCRT and Charité immunology generated spin-offs including ProBioGen AG.
Prof. Dr. Ralf Wagner
Medical microbiology/virology at University of Regensburg. ProBioGen says his team is involved in vaccine research including preclinical and clinical development, and that he served in roles for public-funded vaccine clusters including EU, Gates Foundation, NIH, BMBF and research foundations. He also founded Geneart AG and later served as VP Synthetic Biology after Life Technologies acquired it.
––––––––––
Management-structure change: what changed and when?
The pattern is clear:
▪️ 2024–2025: ProBioGen first brought in Alfred Merz as COO/interim CEO, then elevated him to full CEO effective April 2025.
▪️ September 2025: ProBioGen was selected to operate the GMP manufacturing unit of the Berlin Center for Gene and Cell Therapies, a Charité–BIH–Bayer project.
▪️ April 2026: ProBioGen added Simon Johannes Bulling as COO, shifting Merz into a cleaner CEO role and putting a specialist in GMP scale-up, multi-site operations and biologics manufacturing into the operational seat.
So the company moved from founder/science-driven CDMO Charité-origin story toward a more institutional structure:
▪️ CEO with Bayer/Novartis background
▪️ COO with Celonic/Recipharm/Rentschler/Vetter/Sandoz background
and a supervisory board that combines Minapharm/Africa biologics, Charité/BIH immunology, vaccine/Gates-linked cluster experience, and life-science finance.
How this aligns with the Ebola case in Berlin
The alignment is contextual and infrastructural, not evidence of direct involvement.
The current Berlin Ebola case involves U.S. missionary physician Dr. Peter Stafford, infected while treating patients in the DRC.
Reuters reports that he is being treated at Charité Berlin, with his wife and four children also admitted to an isolation ward as close contacts; the outbreak involves a rare Ebola strain and has killed more than 130 people.
The ProBioGen relevance is that, in the same Berlin–Charité ecosystem, ProBioGen has just been positioned as a major GMP manufacturing operator for advanced therapies at the BC GCT, a Charité/BIH/Bayer-linked infrastructure project.
The BC GCT project is not about Ebola treatment per se; it is about gene and cell therapies, viral vectors, GMP production, clinical material, and translational medicine.
The investigative framing would be:
Within months of ProBioGen formalizing its role as GMP operator for a Charité–BIH–Bayer advanced-therapy hub, and days after ProBioGen installed a new COO specialized in GMP scale-up and biologics manufacturing, Berlin became the European treatment site for a high-profile Ebola evacuation from the DRC.
This does not prove operational involvement by ProBioGen, but it places the company’s management restructuring inside the same Berlin biomedical-security ecosystem: Charité isolation medicine, BIH translation, Bayer-linked advanced-therapy infrastructure, viral-vector/vaccine manufacturing capability, and Africa-facing biologics networks through Minapharm.
2
14
39
869
May 20
Thank you to @HCWCO for the opportunity to participate in the 4th Annual BioConnect Investor Conference.
If you missed our fireside chat, the replay is now available — hear from our team on the latest progress across our icovamenib and BMF-650 programs.
Watch the replay here: bit.ly/biomea-hcwainwright-2…
#BiomeaFusion #HCWainwright #icovamenib #BMF650 #WeAimToCure
1
6
267
May 20
Proper buzz from Nuvectis Pharma yesterday at the HC Wainwright BioConnect Conference. They’ve said preliminary efficacy data from Study 1b is landing end of July or first few days of August.
About time we got some good news on this one 🇬🇧🚀 $NVCT
5
511
May 19
Sgmt ceo H.C. Wainwright'ın 4. Annual BioConnect Investor konferansında konuşuyor. Ortadaki
3
1
33
4,234
May 19
I am pleased to observe that @CardiolRx will participate in a Fireside Chat at the @HCWCO 4th Annual BioConnect Investor Conference today at the Nasdaq in New York City.
The session will commence at 1:30 p.m. Eastern Time, providing insights into their anti-inflammatory and anti-fibrotic therapies targeting heart disease. A webcast replay will be accessible for a period of 90 days.
Register here: journey.ct.events/view/8d043…
$SPY $TSLA $AMZN $GOOGL $QQQ $HOOD $NVDA $AAPL $MFST $AMD $META $PLTR $CAR $BYND $OPEN $RKLB $ASTS $MVRL $QCOM
$CRDL I’m excited to see @CardiolRx participating in a Fireside Chat at the @HCWCO 4th Annual BioConnect Investor Conference today at the Nasdaq in NYC!
Tune in live at 1:30 p.m. ET for insights into their anti-inflammatory & anti-fibrotic therapies for heart disease. Webcast replay available for 90 days.
Register here journey.ct.events/view/8d043… #Ad
Not investment advice. See disclosures.
#CardiolRx #HeartDisease #Biotech
7
1,667
$CRDL I’m excited to see @CardiolRx participating in a Fireside Chat at the @HCWCO 4th Annual BioConnect Investor Conference today at the Nasdaq in NYC!
Tune in live at 1:30 p.m. ET for insights into their anti-inflammatory & anti-fibrotic therapies for heart disease. Webcast replay available for 90 days.
Register here journey.ct.events/view/8d043… #Ad
Not investment advice. See disclosures.
#CardiolRx #HeartDisease #Biotech
$CRDL Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association
The peer-reviewed publication highlights clinical findings demonstrating that treatment with CardiolRx™ was associated with rapid and sustained reductions in pericarditis pain and inflammation in patients with a high baseline disease burden. The study also reported a substantial reduction in pericarditis episodes per year and a favorable safety and tolerability profile, supporting its continued development in a Phase III program. These findings provide important clinical rationale for the ongoing pivotal Phase III MAVERIC trial ("MAVERIC"), evaluating CardiolRx™ in patients with recurrent pericarditis, which recently surpassed 75% enrollment.
"The upcoming publication provides important independent validation of the clinical findings generated in our Phase II MAvERIC study and further supports the potential of CardiolRx™ as a differentiated, non-immunosuppressive therapy for recurrent pericarditis," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics.
"Publication in the Journal of the American Heart Association underscores the clinical relevance of the observed reductions in pericarditis pain and inflammation, together with the favorable safety and tolerability profile demonstrated in this patient population. We believe these data strengthen the foundation for MAVERIC and reinforce the broader opportunity for CardiolRx™ to address a significant unmet medical need in recurrent pericarditis."
The Phase II MAvERIC results published in JAHA represent another important step in advancing clinical understanding of the potential role of CardiolRx™ in the treatment of inflammation-driven heart diseases and helped inform the design and advancement of MAVERIC, a randomized, double-blind, placebo-controlled, pivotal Phase III trial evaluating CardiolRx™ for the prevention of recurrent pericarditis.
@CardiolRx #pericarditis
14
7,055
May 19
Join us for a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at the Nasdaq today at 10:30-11:00 AM ET to hear our latest news and updates. journey.ct.events/view/46141…
$URGN
3
225
REMINDER: Cardiol Therapeutics will be presenting a Fireside Chat today at 1:30 p.m. ET at the H.C. Wainwright 4th Annual BioConnect Investor Conference at the Nasdaq in New York City. $CRDL
📺Watch our Fireside Chat live via webcast — register here:
journey.ct.events/view/8d043…
2
8
4,878
Caribou is participating in the @HCWCO 4th Annual BioConnect Investor Conference. Tune in to the fireside chat tomorrow with our CMO, Tina Albertson, and our CFO, Sri Ryali.
Access the webcast here: bit.ly/4uV0IAu #CellTherapy #CRISPR $CRBU
2
8
1,456
May 15
Biomea Fusion leadership will be participating in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference. We look forward to sharing updates on our mission to restore health for patients living with diabetes, obesity, and related conditions.
🗓 Tuesday, May 19th
⏰ 3:00–3:30 PM ET | 12:00–12:30 PM PT
📍 NASDAQ World Headquarters, New York, NY
Register → bit.ly/biomea-hcwainwright-2…
A replay will be available on the Biomea Fusion website.
For 1:1 meeting requests, please reach out to Meichiel Weiss, Sr. Director of Investor Relations & Corporate Development, at mweiss@biomeafusion.com.
#BiomeaFusion #HCWainwright #BioConnect #Biotech #MetabolicDisease #WeAimToCure
4
329
$CRDL Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ
New York, NY, on May 19, 2026, at 1:30 p.m. EDT.
cardiolrx.com/cardiol-therap…
1
9
2,875
We're pleased to share that Cardiol Therapeutics will participate in a Fireside Chat at the @HCWCO 4th Annual BioConnect Investor Conference, hosted at the @Nasdaq in New York City.
Tune in on May 19 at 1:30 p.m. ET via live webcast.
A replay will be available for 90 days. $CRDL
cardiolrx.com/cardiol-therap…
1
8
4,677
Heading to NYC next week for the @HCWCO 4th Annual BioConnect Investor Conference.
Learn more: bit.ly/4nt84J4 #CellTherapy #CRISPR $CRBU
2
10
1,136
May 13
$BMEA management will be presenting at two upcoming investor conferences. Join us for our fireside chats and one-on-one meetings in New York, NY:
• H.C. Wainwright 4th Annual BioConnect Investor Conference | May 19, 2026 | 3:00–3:30 PM ET
• Jefferies Global Healthcare Conference | June 4, 2026 | 8:10–8:40 AM ET
Audio webcasts as well as replays will be available. Visit our Investors & Media page for details.
For 1:1 meeting requests, please reach out to Meichiel Weiss, Sr. Director of Investor Relations & Corporate Development, at mweiss@biomeafusion.com.
Read the full press release: bit.ly/biomea-press-release-…
#BiomeaFusion #BMEA #HCWainwright #JefferiesHealthcare #WeAimToCure
2
5
567
May 12
Hansa Biopharma ($HNSA) sera à la 4e conférence BioConnect de H.C. Wainwright au Nasdaq (NY) ! 🇺🇸
Maria Törnsén (COO) participera à un "fireside chat" le mardi 19 mai (17h-17h30 EDT). Un moment clé pour la stratégie US de la biotech suédoise. 🧬📈
#HansaBiopharma #Nasdaq #HNSA
2
236
May 12
We’re participating in the @HCWCO BioConnect Investor Conference this week! Lexicon management will join a fireside chat on May 19 at Nasdaq HQ in NYC. For more: investors.lexpharma.com/news… #HCWConference
1
2
6
121